Skrahina V, Grittner U, Beetz C, Skripuletz T, Juenemann M, Krämer HH, Hahn K, Rieth A, Schaechinger V, Patten M, Tanislav C, Achenbach S, Assmus B, Knebel F, Gingele S, Skrahin A, Hartkamp J, Förster TM, Roesner S, Pereira C, Rolfs A (2021) Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology. Ann Med 53(1):1787–1796. https://doi.org/10.1080/07853890.2021.1988696

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dyck PJB, Coelho T, Waddington Cruz M, Brannagan TH 3rd, Khella S, Karam C, Berk JL, Polydefkis MJ, Kincaid JC, Wiesman JF, Litchy WJ, Mauermann ML, Ackermann EJ, Baker BF, Jung SW, Guthrie S, Pollock M, Dyck PJ (2020) Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosis. Muscle Nerve 62(4):509–515. https://doi.org/10.1002/mus.27023

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ando Y, Adams D, Benson MD, Berk JL, Planté-Bordeneuve V, Coelho T, Conceição I, Ericzon BG, Obici L, Rapezzi C, Sekijima Y, Ueda M, Palladini G, Merlini G (2022) Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. Amyloid 29(3):143–155. https://doi.org/10.1080/13506129.2022.2052838

Article  CAS  PubMed  Google Scholar 

Adams D, Algalarrondo V, Polydefkis M, Sarswat N, Slama MS, Nativi-Nicolau J (2021) Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression. Orphanet J Rare Dis 16(1):411. https://doi.org/10.1186/s13023-021-01960-9

Article  PubMed  PubMed Central  Google Scholar 

Adams D, Ando Y, Beirao JM, Coelho T, Gertz MA, Gillmore JD, Hawkins PN, Lousada I, Suhr OB, Merlini G (2021) Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol 268(6):2109–2122. https://doi.org/10.1007/s00415-019-09688-0

Article  PubMed  Google Scholar 

Schmidt HH, Waddington-Cruz M, Botteman MF, Carter JA, Chopra AS, Hopps M, Stewart M, Fallet S, Amass L (2018) Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. Muscle Nerve 57(5):829–837. https://doi.org/10.1002/mus.26034

Article  CAS  PubMed  PubMed Central  Google Scholar 

Conceição I, González-Duarte A, Obici L, Schmidt HH, Simoneau D, Ong ML, Amass L (2016) “Red-flag” symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst 21(1):5–9. https://doi.org/10.1111/jns.12153

Article  CAS  PubMed  PubMed Central  Google Scholar 

Planté-Bordeneuve V, Kerschen P (2013) Transthyretin familial amyloid polyneuropathy. Handb Clin Neurol 115:643–658. https://doi.org/10.1016/b978-0-444-52902-2.00038-2

Article  PubMed  Google Scholar 

Jang SC, Nam JH, Lee SA, An D, Kim HL, Kwon SH, Lee EK (2022) Clinical manifestation, economic burden, and mortality in patients with transthyretin cardiac amyloidosis. Orphanet J Rare Dis 17(1):262. https://doi.org/10.1186/s13023-022-02425-3

Article  PubMed  PubMed Central  Google Scholar 

Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, Heneghan MA, Gorevic PD, Litchy WJ, Wiesman JF, Nordh E, Corato M, Lozza A, Cortese A, Robinson-Papp J, Colton T, Rybin DV, Bisbee AB, Ando Y, Ikeda S, Seldin DC, Merlini G, Skinner M, Kelly JW, Dyck PJ (2013) Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 310(24):2658–2667. https://doi.org/10.1001/jama.2013.283815

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Planté-Bordeneuve V, Lozeron P, Suhr OB, Campistol JM, Conceição IM, Schmidt HH, Trigo P, Kelly JW, Labaudinière R, Chan J, Packman J, Wilson A, Grogan DR (2012) Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 79(8):785–792. https://doi.org/10.1212/WNL.0b013e3182661eb1

Article  CAS  PubMed  PubMed Central  Google Scholar 

Patirisan PI. Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210922s012lbl.pdf. Accessed 9 May 2024

Inotersen PI. Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211172s014lbl.pdf. Accessed 9 May 2024

Vutrisiran PI. Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215515s002lbl.pdf. Accessed 9 May 2024

Coelho T, Ando Y, Benson MD, Berk JL, Waddington-Cruz M, Dyck PJ, Gillmore JD, Khella SL, Litchy WJ, Obici L, Monteiro C, Tai LJ, Viney NJ, Buchele G, Brambatti M, Jung SW, St L, O’Dea L, Tsimikas S, Schneider E, Geary RS, Monia BP, Gertz M (2021) Design and rationale of the global phase 3 NEURO-TTRansform study of antisense oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in hereditary transthyretin-mediated amyloid polyneuropathy. Neurol Ther 10(1):375–389. https://doi.org/10.1007/s40120-021-00235-6

Article  PubMed  PubMed Central  Google Scholar 

Viney NJ, Guo S, Tai LJ, Baker BF, Aghajan M, Jung SW, Yu RZ, Booten S, Murray H, Machemer T, Burel S, Murray S, Buchele G, Tsimikas S, Schneider E, Geary RS, Benson MD, Monia BP (2021) Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data. ESC Heart Fail 8(1):652–661. https://doi.org/10.1002/ehf2.13154

Article  PubMed  Google Scholar 

Wang Y, Yu RZ, Henry S, Geary RS (2019) Pharmacokinetics and clinical pharmacology considerations of GalNAc(3)-conjugated antisense oligonucleotides. Expert Opin Drug Metab Toxicol 15(6):475–485. https://doi.org/10.1080/17425255.2019.1621838

Article  CAS  PubMed  Google Scholar 

Brannagan TH 3rd, Berk JL, Gillmore JD, Maurer MS, Waddington-Cruz M, Fontana M, Masri A, Obici L, Brambatti M, Baker BF, Hannan LA, Buchele G, Viney NJ, Coelho T, Nativi-Nicolau J (2022) Liver-directed drugs for transthyretin-mediated amyloidosis. J Peripher Nerv Syst 27(4):228–237. https://doi.org/10.1111/jns.12519

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coelho T, Marques W Jr, Dasgupta NR, Chao CC, Parman Y, França MC Jr, Guo YC, Wixner J, Ro LS, Calandra CR, Kowacs PA, Berk JL, Obici L, Barroso FA, Weiler M, Conceição I, Jung SW, Buchele G, Brambatti M, Chen J, Hughes SG, Schneider E, Viney NJ, Masri A, Gertz MR, Ando Y, Gillmore JD, Khella S, Dyck PJB, Waddington Cruz M, NEURO-TTRansform Investigators (2023) Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy. JAMA 330(15):1448–1458. https://doi.org/10.1001/jama.2023.18688

Article  CAS  PubMed  PubMed Central  Google Scholar 

Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Plante-Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheinberg M, Brannagan TH 3rd, Litchy WJ, Whelan C, Drachman BM, Adams D, Heitner SB, Conceicao I, Schmidt HH, Vita G, Campistol JM, Gamez J, Gorevic PD, Gane E, Shah AM, Solomon SD, Monia BP, Hughes SG, Kwoh TJ, McEvoy BW, Jung SW, Baker BF, Ackermann EJ, Gertz MA, Coelho T (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 379(1):22–31. https://doi.org/10.1056/NEJMoa1716793

Article  CAS  PubMed  Google Scholar 

Coelho T, Waddington Cruz M, Chao CC, Parman Y, Wixner J, Weiler M, Barroso FA, Dasgupta NR, Jung SW, Schneider E, Viney NJ, Dyck PJB, Ando Y, Gillmore JD, Khella S, Gertz MA, Obici L, Berk JL (2023) Characteristics of patients with hereditary transthyretin amyloidosis-polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an open-label phase 3 study of eplontersen. Neurol Ther 12(1):267–287. https://doi.org/10.1007/s40120-022-00414-z

Article  PubMed  Google Scholar 

Dyck PJB, Gonzalez-Duarte A, Obici L, Polydefkis M, Wiesman JF, Antonino I, Litchy WJ, Dyck PJ (2019) Development of measures of polyneuropathy impairment in hATTR amyloidosis: from NIS to mNIS + 7. J Neurol Sci 405:116424. https://doi.org/10.1016/j.jns.2019.116424

Article  CAS  PubMed  Google Scholar 

Suhr O, Danielsson A, Holmgren G, Steen L (1994) Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy. J Intern Med 235(5):479–485. https://doi.org/10.1111/j.1365-2796.1994.tb01106.x

Article  CAS  PubMed  Google Scholar 

Baker BF, Xia S, Partridge W, Kwoh TJ, Tsimikas S, Bhanot S, Geary RS (2023) Integrated assessment of phase 2 data on GalNAc(3)-conjugated 2’-O-methoxyethyl-modified antisense oligonucleotides. Nucleic Acid Ther 33(1):72–80. https://doi.org/10.1089/nat.2022.0044

Article  CAS  PubMed  Google Scholar 

Narayanan P, Curtis BR, Shen L, Schneider E, Tami JA, Paz S, Burel SA, Tai LJ, Machemer T, Kwoh TJ, Xia S, Shattil SJ, Witztum JL, Engelhardt JA, Henry SP, Monia BP, Hughes SG (2020) Underlying immune disorder may predispose some transthyretin amyloidosis subjects to inotersen-mediated thrombocytopenia. Nucleic Acid Ther 30(2):94–103. https://doi.org/10.1089/nat.2019.0829

Article  CAS  PubMed  Google Scholar